While healthcare organizations and providers are addressing strategies for engaging patient populations in the pursuit of incentive or value-based reimbursements, payers are actively looking for ways to engage this same population as consumers in the name of healthcare reform.
While healthcare organizations and providers are addressing strategies for engaging patient populations in the pursuit of incentive or value-based reimbursements, payers are actively looking for ways to engage this same population as consumers in the name of healthcare reform.
“I see it becoming increasingly important and payers will spend more money on consumer portals and mobile strategies all aimed at consumer engagement but also look at what is happening with the public exchanges,” says IDC Health Insights Analyst Deanne Kasim.
The Accountable Care Act (ACA) is responsible for removing barriers between payers and consumers and as a result payers have had to identify methods for engaging these individuals directly.
Read the full story here: http://bit.ly/1p1YZ56
Source: EHR Intelligence
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More